SCHEMBL4663802

SCHEMBL4663802

CN1CCC(CCn2ccc3cc(-c4cc(Nc5ccc(N(OC=O)S(=O)(=O)c6ccc(F)c(Cl)c6)cc5)ncn4)ccc32)CC1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 1/20 0.35
EGFR P00533 7/20 0.35
ABL1 P00519 5/20 0.33
BCR P11274 5/20 0.33
ERBB2 P04626 2/20 0.33
HPGD P15428 1/20 0.33
HTT P42858 1/20 0.33
TNNI3K Q59H18 3/20 0.33
GSK3B P49841 1/20 0.33
MEN1 O00255 1/20 0.32
USP2 O75604 1/20 0.32
ALDH1A1 P00352 1/20 0.32
TP53 P04637 1/20 0.32
CYP1A2 P05177 1/20 0.32
GLA P06280 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
ALOX15 P16050 1/20 0.32
MAPK1 P28482 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4664241 0.95 AXL (0.36) AXLEGFRABL1BCRERBB2
SCHEMBL4667502 0.90 EGFR (0.36) AXLEGFRABL1BCRERBB2
SCHEMBL4666028 0.89 ABL1 (0.38) ABL1BCRTNNI3K
SCHEMBL4663827 0.89 ABL1 (0.36) EGFRABL1BCRMEN1USP2
SCHEMBL4665757 0.89 HTR6 (0.35) AXLEGFRABL1BCRMEN1
SCHEMBL4664278 0.89 ABL1 (0.35) EGFRABL1BCRMEN1USP2
SCHEMBL4666040 0.88 MEN1 (0.36) EGFRABL1BCRMEN1USP2
SCHEMBL4666112 0.88 EGFR (0.39) EGFRABL1BCRTNNI3KMEN1
SCHEMBL4665687 0.87 MEN1 (0.39) EGFRABL1BCRMEN1USP2
SCHEMBL4667453 0.86 ABL1 (0.34) EGFRABL1BCRMEN1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors ALTANA PHARMA AG (DE) 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors MAP3K19, MAP3K6, MAP3K20 AXL 223/4885EGFR 279/4885ABL1 24/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.